Chief Science Officer, Head of Global Discovery, Early Development & CMC
Teva Pharmaceuticals
West Chester, Pennsylvania
Dr. Steffen Nock is the Chief Scientific Officer at Teva Pharmaceuticals and has more than 25 years of experience in the Biotech and Pharmaceutical industry. During his 12 year tenure at Teva he had positions with increasing responsibility primarily in the development of therapeutic antibodies. His responsibilities includes all aspects of early biologics development from the initial identification through to lead discovery, optimization, pre-clinical development, CMC and bioassays to support clinical studies. He is also responsible for Teva’s Biosimilar programs. He currently leads a global team of about 500 scientists.
Steffen became part of the Teva organization through the acquisition of Cephalon in 2011 where he was head of the Biologics Division. Prior to that he was the CEO of Arana Therapeutics, an Australian public company, when it was acquired in 2009 by Cephalon Inc. Before Arana, he held various positions in the Biotech industry including VP of Biochemistry at Zyomyx Inc., a venture-backed proteomics company in Hayward, California, which he cofounded in 1998. Dr. Nock received his Ph.D. in 1996 at the University of Bayreuth, Germany in biochemistry, followed by a two year post doctoral fellowship at Stanford University.
Disclosure information not submitted.
Novel Approaches to Cancer Immunotherapy: a Strategic Overview
Tuesday, May 14, 2024
9:30 AM – 10:00 AM PT